These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Pancreatic alpha cell glucagon-liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes. Cui X, Feng J, Wei T, Zhang L, Lang S, Yang K, Yang J, Liu J, Sterr M, Lickert H, Wei R, Hong T. Diabetologia; 2023 Mar; 66(3):535-550. PubMed ID: 36331598 [Abstract] [Full Text] [Related]
12. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Conarello SL, Jiang G, Mu J, Li Z, Woods J, Zycband E, Ronan J, Liu F, Roy RS, Zhu L, Charron MJ, Zhang BB. Diabetologia; 2007 Jan; 50(1):142-50. PubMed ID: 17131145 [Abstract] [Full Text] [Related]
13. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Diabetes; 2011 Feb; 60(2):391-7. PubMed ID: 21270251 [Abstract] [Full Text] [Related]
15. Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia. Kedees MH, Grigoryan M, Guz Y, Teitelman G. Mol Cell Endocrinol; 2009 Nov 13; 311(1-2):69-76. PubMed ID: 19647035 [Abstract] [Full Text] [Related]
16. Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade. Mani BK, Uchida A, Lee Y, Osborne-Lawrence S, Charron MJ, Unger RH, Berglund ED, Zigman JM. Diabetes; 2017 Jul 13; 66(7):1847-1857. PubMed ID: 28487437 [Abstract] [Full Text] [Related]
17. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, Jacobs SJ, Moyers JS, Owens RA, Showalter AD, Brenner MB, Raap A, Gromada J, Berridge BR, Monteith DK, Porksen N, McKay RA, Monia BP, Bhanot S, Watts LM, Michael MD. J Clin Invest; 2004 Jun 13; 113(11):1571-81. PubMed ID: 15173883 [Abstract] [Full Text] [Related]
18. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. Claus TH, Pan CQ, Buxton JM, Yang L, Reynolds JC, Barucci N, Burns M, Ortiz AA, Roczniak S, Livingston JN, Clairmont KB, Whelan JP. J Endocrinol; 2007 Feb 13; 192(2):371-80. PubMed ID: 17283237 [Abstract] [Full Text] [Related]
19. Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose. Zhang Y, Han C, Zhu W, Yang G, Peng X, Mehta S, Zhang J, Chen L, Liu Y. Cells; 2021 Sep 21; 10(9):. PubMed ID: 34572144 [Abstract] [Full Text] [Related]
20. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Longuet C, Robledo AM, Dean ED, Dai C, Ali S, McGuinness I, de Chavez V, Vuguin PM, Charron MJ, Powers AC, Drucker DJ. Diabetes; 2013 Apr 21; 62(4):1196-205. PubMed ID: 23160527 [Abstract] [Full Text] [Related] Page: [Next] [New Search]